Schizophrenia in the practice of a nurse

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Schizophrenia is a complex chronic mental disorder that affects a person’s thinking, perception, emotional state and behavior. Despite significant advances in psychiatry, effective treatment of this disorder remains a real challenge. In this article, we will consider modern approaches to the treatment of schizophrenia, including pharmacological methods, psychotherapy and innovative rehabilitation strategies.

It is estimated that schizophrenia affects about 1% of the world’s population and manifests itself in many forms. Key symptoms include hallucinations, delusions, cognitive impairment, and changes in the emotional sphere. Successful treatment of schizophrenia requires an integrated approach that combines drug therapy with psychosocial interventions.

Full Text

Restricted Access

About the authors

Vsevolod V. Skvortsov

Federal State Budgetary Educational Institution of Нigher Education «Volgograd State Medical University» of the Мinistry of Healthcare of the Russian Federation

Author for correspondence.
Email: vskvortsov1@ya.ru
ORCID iD: 0000-0002-2164-3537
SPIN-code: 7201-2980

Doctor of Medicine, Professor of the Department of Internal Medicine

Russian Federation, Volgograd

Alexey V. Sabanov

Federal State Budgetary Educational Institution of Нigher Education «Volgograd State Medical University» of the Мinistry of Healthcare of the Russian Federation

Email: sabanov@yandex.ru
ORCID iD: 0000-0003-4170-1332
SPIN-code: 2815-3218

Doctor of Medical Sciences, Professor of the Department of Internal Medicine ICMPE

Russian Federation, Volgograd

Dmitry S. Erofeev

Federal State Budgetary Educational Institution of Нigher Education «Volgograd State Medical University» of the Мinistry of Healthcare of the Russian Federation

Email: erofeev89012345@gmail.com
SPIN-code: 8111-4360

3rd year student of the Faculty of Medicine

Russian Federation, Volgograd

Ilya S. Ukhorenko

Federal State Budgetary Educational Institution of Нigher Education «Volgograd State Medical University» of the Мinistry of Healthcare of the Russian Federation

Email: uxorenko@gmail.com
SPIN-code: 1349-1680

3rd year student of the Faculty of Medicine

Russian Federation, Volgograd

References

  1. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins, D.O. Kreyenbuhl J. American Psychiatric Association, & Steering Committee on Practice Guidelines (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. The American journal of psychiatry. 161 (2 Suppl.): 1–56.
  2. Marder S.R. and Cannon T.D. Schizophrenia. The New England journal of medicine. 2019; 381, 1753–1761.
  3. Gu X., Zheng W., Guo T. et al. Electroconvulsive Therapy for Agitation in Schizophrenia: Metaanalysis of Randomized Controlled Trials. Shanghai archives of psychiatry. 2017; (29): 1–14.
  4. Hooley J.M. Expressed emotion and relapse of psychopathology. Annual review of clinical psychology. 2007; (3): 329–352.
  5. Fiszdon J.M., Reddy L.F. Review of social cognitive treatments for psychosis. Clinical psychology review. 2012; (32): 724–740.
  6. Kumar B., Kuhad A. and Kuhad A., Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs of today. 2018; (54): 713–719.
  7. Syed A.B. and Braоiо J.R. The role of lumateperone in the treatment of schizophrenia. Therapeutic advances in psychopharmacology. 2021; (11).
  8. Koblan K.S., Kent J., Hopkins S.C. et al. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. The New England journal of medicine. 2020; (382): 1497–1506.
  9. Lavretsky H. History of Schizophrenia as a Psychiatric Disorder. In: Mueser KT, Jeste DV. Clinical Handbook of Schizophrenia. New York, New York: Guilford Press; 2008; 3–12.
  10. Stahl S.M., Morrissette D.A., Citrome L. et al. Meta-guidelines for the management of patients with schizophrenia. CNS Spectr 2013; 18 (3): 150–162.
  11. Crismon L., Argo T.R., Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, New York: McGraw-Hill; 2014:1019–1046.
  12. American Psychiatric Association. Schizophrenia and other psychotic disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, D.C. American Psychiatric Association; 2013: 89–122.
  13. Lindenmayer J.P., Liu-Seifert H., Kulkarni P.M. et al. Medication nonadherence and treatment outcomes in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009; 70 (7): 990–996.
  14. Klingberg S., Wolwer W., Engel C. et al. Negative Symptoms of Schizophrenia as Primary Target of Cognitive Behavioral Therapy: Results of the Randomized Clinical TONES Study. Schizophrenia bulletin. 2011; 37 (2): 98–110.
  15. Brown G.W., Birley J.L., Wing J.K. Influence of family life on the course of schizophrenic disorders: a replication. British Journal of Psychiatry. 1972; 121 (562): 241–258.
  16. McFarlane W.R., Dixon L., Lukens E. et al. Family psychoeducation and schizophrenia: a review of the literature. Journal of marital and family therapy. 2003; 29 (2): 223–245.
  17. Turner D.T., van der Gaag M., Karyotaki E., Cuijpers P. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. American Journal of Psychiatry. 2014; 171 (5): 523–538.
  18. Kumar B., Kuhad A. and Kuhad A., Lumateperone: a new treatment approach or neuropsychiatric disorders. Drugs of today. 2017; (54): 713–719.
  19. Koblan K.S., Kent J., Hopkins S.C et al. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. The New England journal of medicine 382, 1497–1506. associated receptor 1 modulates dopaminergic activity,» The Journal of pharmacology and experimental therapeutics 324, 948–956.
  20. Espinoza S., Masri B., Salahpour A. and Gainetdinov R.R. BRET approaches to characterize dopamine and TAAR1 receptor pharmacology and signaling. Methods in molecular biology 964, 107–122.
  21. Weeks J.J., Grace A.A. and Sved A.F., Nicotine Administration Normalizes Behavioral and Neurophysiological Perturbations in the MAM Rodent Model of Schizophrenia. The international journal of neuropsychopharmacology 24: 979–987.
  22. Perkins D.O., Jeffries C.D. and Do K.Q. Potential Roles of Redox Dysregulation in the Development of Schizophrenia. Biological psychiatry 88, 326–336.
  23. Rummel-Kluge C, Kissling W. Psychoeducation for patients with schizophrenia and their families. Exp Rev Neurother 2008; 8 (7): 1067–1077.
  24. Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia: 2011 update. J Nerv Ment Dis 2011; 199 (8): 520–526.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russkiy Vrach Publishing House